Accelerate Diagnostics and BioCheck announced commercial supply and collaboration agreement for SARS-CoV-2 antibody tests

On Apr. 15, 2020, Accelerate Diagnostics announced they have entered into a commercial supply and collaboration agreement. Under the agreement, Accelerate Diagnostics will distribute the BioCheck MS-FAST, a fully-automated chemiluminescence immunoassay analyzer, along with BioCheck’s SARS-CoV-2 tests for the detection of IgG and IgM antibodies. The agreement covers North America, Europe and the Middle East.

Tags:


Source: Accelerate Diagnostics
Credit: